Effects of Standard Heparin and a Low Molecular Weight Heparin (Kabi 2165) on Fibrinolysis

Summary

Previous and recent reports have suggested a fibrinolysisenhancing property of standard heparin and low molecular weight heparins, but these observations have never been confirmed in a study fulfilling appropriate methodological criteria. The aim of this study was to evaluate the effect of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis in a randomized cross-over double blind placebo controlled study. Six healthy volunteers received intravenously a bolus dose of the following treatments: placebo; standard heparin, 5,000 I.U.; Kabi 2165, 5,000 anti-Xa U; Kabi 2165,10,000 anti-Xa U. Before the injection and at established times thereafter, blood samples were collected for the following assays in plasma: t-PA activity, PA inhibitor activity, fibrin plate lysis area (FPLA), plasminogen, α₂-antiplasmin, fibrinogen and anti-Xa activity. Placebo and Kabi 2165, 5,000 anti-Xa U, had no effect on t-PA plasma level. Standard heparin and Kabi 2165, 10,000 anti-Xa U, produced a statistically significant increase in t-PA level at 1 hour after the infusion. This increase lasted for at least 1 hour after the infusion. No effect of any treatment on PA inhibitor, plasminogen, FLPA, α₂-antiplasmin and fibrinogen was observed. We conclude that an intravenous bolus dose of both standard heparin, 5,000 I.U. and Kabi 2165, 10,000 anti-Xa U produces a delayed and sustained increase in plasma t-PA.

Keywords

Heparin - Low molecular weight heparin - Fibrinolysis - Tissue-type plasminogen activator

• References

• 1 Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-357
• 2 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
• 3 Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Tromb Res 1983; 30: 219-224
• 4 Halse Th. Aktivierung der Fibrinolyse und Thombolyse durch Polysaccharidschwefelsaureester (Heparin, Heparinoide). Arzneim Forschung 1962; 12: 574-582
• 5 Markwardt F, Klöcking H P. Heparin induced release of plasminogen activator. Haemostasis 1977; 6: 370-374
• 6 Amesen H, Engebretsen LF, Ugland OM, Seljeflot I, Kierulf P. Increased fibrinolytic activity after surgery induced by low dose heparin. Thromb Res 1987; 45: 553-559
• 7 Vinazzer H, Stemberger A, Haas S, Blumel G. Influence of heparin; of different heparin fractions and a low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-352
• 8 Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin. II. Effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
• 9 Klöcking HP, Markwardt F. Pentosan polysulphate induced release of plasminogen activator. Haemostasis 1984; 14: 121
• 10 Marsh NA, Peyser PM, Creighton LJ, Mahmoud M, Gaffney PJ. The effect of pentosan polysulphate (SP54) on the fibrinolytic enzyme system. A human volunteer and experimental study. Thromb Haemostas 1985; 54: 833-837
• 11 Verheijen JH, Mullaart E, Chang GT C, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma. Thromb Haemostas 1982; 48: 266-269
• 12 Kluft C. Cl-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978; 13: 135-151
• 13 Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue-type plasminogen activator. Thromb Haemostas 1985; 53: 134-136
• 14 Verheijen JH, Chang GT C, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 15 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic peptide substrates Scully M, Kakkar VV. (eds) Churchill Livingstone; Edinburgh: 1979: 128-139
• 16 Teger-Nielsson AC, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Lab Invest 1977; 37: 403-409
• 17 Chakrabarti R, Bielawiec M, Evans JF, Feamley GR. Methodological study and a recommended technique for determining the euglobulin lysis time. J Clin Pathol 1968; 21: 698-701
• 18 Teien AN, Lie M, Abilgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-418
• 19 Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50: 1096-1099
• 20 Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-4040
• 21 Neerstrand H, Ostergaard P, Bergqvist D, Matzsch T, Hedner U. PA inhibitor t-PA antigen, plasminogen, and α-2-antiplasmin after low molecular weight heparin or standard heparin. Fibrinolysis 1987; 1: 39-44
• 22 Mannucci PM, Rota L. Plasminogen activator response after DDAVP: a clinico-pharmacological study. Thromb Res 1980; 20: 69-76
• 23 Barzu T, Molho P, Tobelem G, Petitou M, Caen JP. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cell in culture. Nouv Rev Fr Hematol 1984; 26: 243-247
• 24 Rappaport RS, Blume MR, Hung PP. Endothelial cell growth factors and heparin stimulate the synthesis of tissue-type plasminogen activator and pro-urokinase by human diploid fibroblasts. Fibrinolysis 1986; Suppl 1: 110
• 25 Bounameaux H, Lijnen HR, Hellemans H, Verstraete M. Effect of standard and low-molecular weight heparin fractions on fibrinolysis and platelet aggregation in patients undergoing hysterectomy. Thromb Haemostas 1986; 55: 298